ArticleFrontiers in medicine2026
Development of a prognostic model for sepsis based on gut microbiota-associated genes and identification of potential targets.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut microbiota dysbiosis drives sepsis progression by impairing intestinal barrier function and exacerbating systemic inflammation, but the microbiota-host-immune interaction mechanisms remain unclear. Methods: We integrated transcriptomic and single-cell RNA sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between sepsis patients and healthy controls were identified in GSE154918, then intersected with 248 gut microbiota-related genes from the GutMGene database to obtain candidate genes. A prognostic model named GMGscore was constructed via LASSO-Cox regression in GSE65682 and validated in GSE95233. Area under the curve (AUC) was used to evaluate the model performance. The expression of gut microbiota-related genes was validated in peripheral blood samples obtained from patients with sepsis through RT-qPCR. Furthermore, scRNA-seq data (GSE167363) was used to determine the cellular localization of key genes. Molecular docking predicted interactions between gut microbiota metabolites and the key target. Results: We identified 34 gut microbiota-related DEGs, which were enriched in pathways like inflammatory bowel disease and IL-17 signaling. The GMGscore, based on 6 genes (CYP1A2, FFAR2, IL4R, MUC1, RORA, ASPM), showed excellent prognostic performance (AUC = 0.903 in training set; AUC = 0.901 in validation set). High GMGscore correlated with poor survival, upregulated neutrophil degranulation and reduced neutrophils. RORA was identified as a key gut microbiota-related target, which was consistently downregulated in sepsis with the highest diagnostic AUC across datasets, mainly expressed in effector T cells and NK cells, and positively correlated with CD8 + T cell/NK cell infiltration ( Conclusion: The GMGscore is a robust prognostic tool for sepsis. RORA, targeted by gut microbiota metabolites, may regulate immune balance via effector T cells and NK cells. These findings advance understanding of gut microbiota-sepsis crosstalk and provide new avenues for precise prognosis and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.